Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CD200AR-L |
| Synonyms | |
| Therapy Description |
CD200AR-L is a peptide ligand of CD200AR, which potentially enhances antitumor immune response and decreases tumor growth (PMID: 33829411). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CD200AR-L | CD200AR-L hP1A8|hP1A8 | CD200AR-L is a peptide ligand of CD200AR, which potentially enhances antitumor immune response and decreases tumor growth (PMID: 33829411). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06305910 | Phase I | CD200AR-L | CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults | Recruiting | USA | 0 |